Sirius NeoSight
A therapeutic prediction technology platform for oncology, isolating Circulating Tumour Cells by measuring membrane fluidity for detection.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
* | €4.4m | Seed | |
| Total Funding | 000k | ||
Related Content
Sirius NeoSight is a biotechnology company focused on oncology diagnostics. The firm is developing a technology platform designed for therapeutic prediction by isolating Circulating Tumour Cells (CTCs) from blood samples. Its core methodology is based on measuring cell membrane fluidity, which serves as a universal marker to discriminate and purify CTCs. This approach aims to provide a high-performance tool for the detection, monitoring, and therapeutic orientation of cancer patients.
The company targets the oncology market, collaborating with clinical and research institutions such as the Hospices Civils de Lyon (HCL) and the Centre Léon Bérard (CLB). Its business model appears to be centered on the development and eventual commercialization of this proprietary technology platform. Revenue generation will likely stem from selling or licensing its solution to hospitals, clinical laboratories, and pharmaceutical companies involved in oncology research and treatment.
Sirius NeoSight has secured €4.4 million in a financing round to advance the development of its platform. The company is actively engaged in clinical projects, having won an award for its LIGHT CTC project supported by the French National Cancer Institute (INCa), indicating validation from key industry bodies.
Keywords: Oncology, Circulating Tumour Cells, CTCs, Diagnostics, Membrane Fluidity, Therapeutic Prediction, Cancer Detection, Biotech, Medical Technology, Liquid Biopsy